[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dr.dr.Irma Bernadette, SpKK (K)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":185},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,69,104,126,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643341","effectiveness-and-safety-of-a-hydrating-gel-containing-polyvinyl-pyrrolidine-algin-and-hyaluronic-acid-applied-after-and-without-fractional-co-laser-therapy-100643341",false,"NCT07639151","Effectiveness and Safety of a Hydrating Gel Containing Polyvinyl Pyrrolidine, Algin and Hyaluronic Acid Applied After and Without Fractional CO₂ Laser Therapy","Effectiveness and Safety of a Hydrating Gel Containing Aqua, Carrageenan, Polyvinyl Pyrrolidon, Algin, Gellan Gum, and Hyaluronic Acid Applied After and Without Fractional CO₂ Laser Therapy","Inclusion Criteria:\n\n1. Female participants aged 18-60 years.\n2. Patients attending the Dermatology and Venereology Outpatient Clinic of Universitas Indonesia Hospital (RSUI) who will receive the hydrating gel either following fractional CO₂ laser treatment or without undergoing the fractional CO₂ laser procedure.\n3. Patients who will undergo or have undergone a priming regimen with topical retinoic acid preparations at concentrations of at least 0.025%, 0.05%, or 0.1% for at least 2 weeks prior to fractional CO₂ laser treatment, or prior to study participation in the non-laser group.\n4. Willing to participate in the study and have provided written informed consent after receiving adequate explanation regarding the study.\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or currently using oral contraceptives at the time of assessment.\n2. History of systemic retinoid use within the past 3 months.\n3. History of or current treatment for hormonal\u002Fendocrine disorders or other serious medical conditions.\n4. Currently receiving immunosuppressive therapy.\n5. Participants who are unable or unwilling to comply with the study protocol and treatment regimen.",true,"FEMALE","18 Years","60 Years",{"count":21,"type":22},51,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this interventional study is to evaluate the effectiveness and safety of a hydrating gel containing aqua, carrageenan, polyvinyl pyrrolidone, algin, gellan gum, and hyaluronic acid. The study will assess the gel's ability to support optimal skin recovery following fractional CO₂ laser therapy and its effectiveness and safety as a daily adjunctive skincare treatment. Outcomes related to skin hydration, skin barrier function, tolerability, and adverse events will be evaluated throughout the study period.\n\nFemale participants aged 18 to 60 years who provide informed consent will be enrolled in this study. Participants will undergo a 2-week priming period with topical tretinoin prior to fractional CO₂ laser treatment. Clinical evaluations will be performed at baseline, immediately after the laser procedure, and on Days 3, 7, and 14 post-treatment. Assessments conducted by a board-certified dermatologist will include dermoscopy, TEWAmeter assessment, erythema assessment, and evaluation of pain and discomfort using a Visual Analog Scale (VAS).",[28,29,30,31],"Hydration","Carbon-dioxide Laser","Laser Therapy","Hydrogel",[31,33,28],"CO2 Fractional Laser","NOT_YET_RECRUITING","2026-06-05",{"date":37,"type":38},"2026-06-10","ACTUAL",{"date":40,"type":22},"2026-06",{"date":42,"type":22},"2026-09",{"name":44,"class":45},"Dr.dr.Irma Bernadette, SpKK (K)","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100602279","efficacy-and-safety-of-a-combined-serum-containing-melasyl-10-niacinamide-hyaluronic-acid-and-hepes-100602279","NCT07121439","Efficacy and Safety of a Combined Serum Containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES","The Efficacy and Safety of a Combined Serum Containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and Hydroxyethylpiperazine Ethane Sulfonic Acid Following Low-Fluence Q-Switched Nd:YAG 1064 nm Laser Treatment for Melasma and Post-Acne Hyperpigmentation Therapy","Inclusion Criteria:\n\n* Female, aged 18-60 years.\n* Patients diagnosed with post-acne hyperpigmentation and melasma based on clinical examination and Wood's lamp evaluation, with Fitzpatrick skin types IV and V.\n* Patients visiting the Dermatology and Venereology Outpatient Clinic and scheduled to undergo QS Nd:YAG 1064 nm low-fluence laser treatment.\n\nPatients who are currently receiving or have received a priming regimen for at least two weeks prior to the laser procedure, consisting of either 2% hydroquinone cream or a serum containing Niacinamide 10%, Hyaluronic Acid, and HEPES.\n\n\\- Willing to participate in the study and provide written informed consent after receiving a complete explanation of the study procedures.\n\nExclusion Criteria:\n\n* Pregnant, breastfeeding, or currently taking oral contraceptives at the time of evaluation.\n* History of systemic retinoid use within the past three months.\n* History of or ongoing treatment for hormonal\u002Fendocrine disorders or other severe systemic illnesses.\n* Currently undergoing immunosuppressive therapy.\n* Difficulty adhering to treatment protocols.",{"count":55,"type":22},68,[25],"The goal of this clinical trial is to evaluate the efficacy and safety of a combination serum containing Melasyl™, 10% Niacinamide, Hyaluronic Acid, and HEPES when used as a moisturizer after QS-Nd:YAG 1064 nm low-fluence laser treatment for melasma and post-acne hyperpigmentation.\n\nThe study aims to answer the following main questions:\n\n* Does the combination serum reduce hyperpigmented lesions after laser treatment for melasma and post-acne hyperpigmentation?\n* Does the serum improve skin hydration following laser therapy for melasma?\n* Is the combination serum safe for use after laser treatment, without causing irritation or adverse effects?\n\nParticipants will be female patients aged 18-60 years, clinically diagnosed with melasma or post-acne hyperpigmentation (skin types IV and V), who visit the Dermatology \\& Venereology Outpatient Clinic for QS-Nd:YAG 1064 low-fluence laser treatment. All participants will have undergone a 2-week priming period using either 2% hydroquinone cream or the test serum prior to laser treatment. Written informed consent is required.\n\nParticipants will be randomly assigned to receive either the test serum or 2% hydroquinone cream based on a coded allocation. The product will be applied twice daily after facial cleansing, and sunscreen will be used 15 minutes before outdoor activities. Treatment lasts for 2 weeks, with participants recording application times and any adverse effects in a diary. Evaluations-including facial photography, mMASI, mexameter, dermoscopy, Wood's lamp, and PAHPI-will be conducted at baseline and at 1, 2, and 4 weeks post-laser. Erythema and subjective assessment (VAS) will be performed 15 minutes after the laser procedure.",[59,60],"Melasma","Post-acne Hyperpigmentation","2025-08-06",{"date":63,"type":38},"2025-08-13",{"date":65,"type":22},"2025-09-15",{"date":67,"type":22},"2025-12-01",{"name":44,"class":45},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":46},"100575671","phase-3-the-effectiveness-and-safety-of-cleanser-containing-triethyl-citrate-pyruvic-acid-combination-cream-containing-triethyl-citrate-ethyl-linoleate-gt-peptide-10-salicylic-acid-05-zinc-lactate-hyaluronic-acid-and-spot-cream-containing-triethyl-citrate-ethyl-linoleate-gt-peptide-10-honokiol-100575671","NCT06775314","The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol","The Effectiveness and Safety of Cleanser Containing Triethyl Citrate, Pyruvic Acid, Combination Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Salicylic Acid 0,5%, Zinc Lactate, Hyaluronic Acid and Spot Cream Containing Triethyl Citrate, Ethyl Linoleate, GT Peptide-10, Honokiol As Adjuvant Therapy for Mild to Moderate Acne Vulgaris","Inclusion Criteria:\n\n* Female and male aged 15-50 years\n* mild to moderate acne vulgaris according to IAEM (Indonesian Acne Expert Meeting) scale and GEA ( Global Acne Severity) scale\n* The subject is willing to participate in the study until it is finished\n\nExclusion Criteria:\n\n* History of allergy to dermocosmetic products\n* Undergoing other acne therapy, medication, or invasive action in the last month\n* Pregnant or breastfeeding subjects","ALL","15 Years","50 Years",{"count":80,"type":22},102,[82],"PHASE3","The goal of this clinical study is to learn the effectiveness and safety of Cleanser containing Triethyl citrate, Pyruvic acid, Combination cream containing Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic acid 0,5%, Zinc lactate, Hyaluronic acid and Spot cream containing Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol as Adjuvant Therapy for Mild to Moderate Acne Vulgaris. This research aims to answer the main questions, those are :\n\n1. How is the effectiveness of Cleanser containing Triethyl citrate, Pyruvic acid, Combination cream containing Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic acid 0,5%, Zinc lactate, Hyaluronic acid and Spot cream containing Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol as Adjuvant Therapy for Mild to Moderate Acne Vulgaris?\n2. How is the safety of Cleanser containing Triethyl citrate, Pyruvic acid, Combination cream containing Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic acid 0,5%, Zinc lactate, Hyaluronic acid and Spot cream containing Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol as Adjuvant Therapy for Mild to Moderate Acne Vulgaris?\n\nParticipants are males and females between 15-50 years old. Participants will be examined by dermatologist, and will be photographed in five different positions, and also evaluated by janus facial analysis system. The participants are asked to use Cleanser containing Triethyl citrate, Pyruvic acid, Combination cream containing Triethyl citrate, Ethyl linoleate, GT peptide-10, Salicylic acid 0,5%, Zinc lactate, Hyaluronic acid and Spot cream containing Triethyl citrate, Ethyl linoleate, GT peptide-10, Honokiol as Adjuvant Therapy. The participants will be evaluated in 28, 56 and 84 days after the treatment.",[85],"Acne Vulgaris",[87,88,89,90,91,92,93,94,95],"acne vulgaris","Triethyl citrate","Pyruvic acid","Ethyl linoleate","GT peptide-10","Salicylic acid 0,5%","Zinc lactate","Hyaluronic acid","Honokiol","2025-01-14",{"date":98,"type":38},"2025-01-16",{"date":100,"type":22},"2025-03-01",{"date":102,"type":22},"2025-06-30",{"name":44,"class":45},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":16,"sex":17,"minAge":110,"maxAge":19,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100555771","development-of-products-based-on-secretom-from-stem-cell-conditioned-medium-for-melasma-therapy-100555771","NCT06516419","Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy","Inclusion Criteria:\n\n* Women diagnosed with melasma.\n* Women without melasma and have areas of skin that are clinically free of lesions for SP control.\n* 30-60 years old.\n* Fitzpatrick skin type IV-V.\n* Willing to be a research subject by signing a research consent form (Informed Consent).\n\nExclusion Criteria:\n\n* Pregnant and breastfeeding women.\n* Currently using hormonal contraception or have ever used contraception hormones in the last 6 months.\n* Using topical therapy for melasma, for example corticosteroids, tretinoin, hydroquinone, and other therapies that whiten or brighten the skin in the last 2 weeks.\n* Using topical triple combination cream therapy for at least 3 months and did not show significant improvement\n* Using systemic therapy for melasma, for example antioxidants or tranexamic acid in the last 4 weeks.\n* History of superficial peeling therapy in the last 4 weeks.\n* History of deep peeling therapy, laser or mechanical abrasion in the last 6 months.\n* Using drugs that are photosensitizers such as tetracycline, phenytoin, carbamazepine, spironolactone.\n* History of blood clotting disorders or on blood thinning therapy.\n* Allergy to tranexamic acid.\n* Have other skin complaints that may interfere with the evaluation of melasma, for example post-inflammatory hyperpigmentation, Hori's nevus, Ota's nevus, pigmented contact dermatitis, and other pigmentation disorders\n* Difficulty complying with treatment.","30 Years",{"count":112,"type":22},90,[25],"This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in RSCM-FKUI\n\nThis study aims to Assess the effectiveness and safety of intradermal concentrated secretome injection therapy, triple combination cream, and intradermal tranexamic acid injection in melasma patients, determine the quality of life profile of melasma patients after triple combination cream therapy in melasma therapy, and determine SOD levels in melasma patients.\n\nThis research will be attended by 90 research subjects",[59],"RECRUITING","2024-07-18",{"date":119,"type":38},"2024-07-24",{"date":121,"type":38},"2024-02-13",{"date":123,"type":22},"2025-03-30",{"name":44,"class":45},2,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":16,"sex":76,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":46},"100554627","association-of-leucocyte-telomere-length-with-dpas-score-in-skin-aging-100554627","NCT06501547","Association of Leucocyte Telomere Length With DPAS Score in Skin Aging","Association of Leucocyte Telomere Length With Clinical Examination and Dermoscopic Photoaging Scale (DPAS) Score in Skin Aging: a Pilot Study","Inclusion Criteria:\n\n* Female and Male (age 29-31 years old and 59-61 years old\n* signs of aging\n\nExclusion Criteria:\n\n* pregnant or breastfeeding\n* have disease or genetic problem","29 Years","61 Years",{"count":136,"type":22},20,[25],"The goal is to know the profile of photoaging based on clinical examination, Dermoscopic Photoaging Scale and leucocyte telomere length\n\nThe main questions of Research are:\n\n* what is the profile of photoaging based on clinical examination results in skin aging\n* what is the profile of photoaging based on DPAS Score in skin aging\n* what is the profile of leucocyte telomere length in skin aging\n\nParticipants are female and male with the age of 29-31 years old and 59-61 years old. They will be examined by dermatovenereologist and will be photographed in 5 positions, they will get dermocopy on forehead, right cheek , left cheek, and chin, and their blood will be drawn about 10 mL in order to get the profile of leucocyte telomere length",[140,141],"Aging","Skin Laxity",[143,144,145,146,147,148,149,150],"Dermoscopy","Dermoscopic photoaging scale (DPAS)","Glogau scale","Leucocyte telomere length (LTL)","Photoaging","Skin aging","Telomere","Ultraviolet (UV)","2024-07-09",{"date":153,"type":38},"2024-07-15",{"date":155,"type":38},"2023-10-01",{"date":157,"type":22},"2024-09-01",{"name":44,"class":45},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":16,"sex":76,"minAge":166,"maxAge":19,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":116,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":184,"locationsCount":46},"100554628","profiles-analysis-of-genome-wide-association-study-gwas-in-acne-vulgaris-in-indonesia-100554628","NCT06501560","Profiles Analysis of Genome Wide Association Study (GWAS) in Acne Vulgaris in Indonesia.","Profiles Analysis of Genome Wide Association Study (GWAS) in Acne Vulgaris in Indonesia","Inclusion Criteria:\n\n* Males or females with AVB aged 17-21 years\n* Both parents of complete subjects with or without a history of acne vulgaris aged up to 60 years\n* Patients and parents are willing to participate in the study and sign informed consent.\n\nExclusion Criteria:\n\n* Patients who have other inflammatory or infectious diseases especially on the face\n* Have genetic diseases or disorders\n* Diagnosed with primary or secondary immunodeficiency diseases\n* Using oral or systemic antibiotic, anti-inflammatory, retinoid or hormone therapy in the past month.","17 Years",{"count":168,"type":22},24,[25],"This study is a series of descriptive-analytic studies on genomic variants in the facial skin of patients with AV at the Dermatology and Venereology Polyclinic by determining the genetic profile by GWAS examination in AVB and analysing the genetic profile in AVB against differences in geographical location. The research design used was a cross-sectional design.",[85],[173,174,175,176,177,178,179],"Acne","Acne Vulgaris (AV)","Genome Wide Association Study (GWAS)","Genetic","Genotype","Deoxyribonucleic Acid (DNA)","Single Nucleotide Polymorphism (SNP)",{"date":153,"type":38},{"date":155,"type":38},{"date":183,"type":22},"2024-08-17",{"name":44,"class":45},""]